Research > ETFs > ETF / ETP Commentary > 

Biotech Small Caps Will Bounce Back

Large cap biotechnology have strengthened in recent months, but smaller counterparts are still waiting on their 2021 moment. When that happens, the Defiance Nasdaq Junior Biotechnology ETF (IBBJ) could be the ETF to watch.IBBJ follows the Nasdaq Junior Biotechnology Index (NBIJR), the small cap offshoot of the widely tracked Nasdaq Biotechnology Index (NBI). The junior index limits components’ market values to $5 billion when those names are admitted. That cap can bear fruit for investors.“Small-cap biotech companies have the potential advantage of a Food & Drug Administration (FDA) more receptive to cutting-edge and rare diseases therapies,” according to Defiance ETFs. “They are also strengthened by increased patient lobbying and greater willingness by insurers to pay for treatments.”That’s a potential point in IBBJ’s favor because many large cap biotech exchange traded funds are dominated by companies that have already experienced significant market capitalization growth. As Defiance points out, the total value of the global pharmaceutical market was $390 billion in 2001, but it soared to $1.25 trillion at the end of 2019.In other words, it’s good to get involved early with the right biotechnology companies, but stock-picking to that effect in this industry is difficult. IBBJ eases the burden.“Owing to the fact that many small biotechnology companies aren’t profitable, earnings reports don’t mean much in this space,” according to Nasdaq. “The primary catalysts for upside in these stocks, including IBBJ components, are the aforementioned of trial and FDA news and mergers and acquisitions activity."IBBJ offers investors another potentially significant benefit: considerable leverage to industry consolidation. Said another way, by capping components at market caps of $5 billion, IBBJ could be fertile territory for large cap biotechnology and pharmaceuticals companies looking to make deals. In fact, IBBJ’s much of IBBJ’s roster could be attractive to other healthcare sector suitors.“More than 90% of life sciences M&A is for deals of less than $500 million, and they usually consist of pharmaceutical companies making acquisitions of pre-commercial middle market companies,” writes Adam Lohr of RSM US LLP.Mid- and small-cap biotechnology names are often the centers of takeover of rumors, but deal-making has been slow this year. However, that could change before the end of 2021.“In April, Moody’s Investors Service said Amgen, Bristol Meyers Squibb, Johnson & Johnson, and Merck are among the large-cap healthcare companies with the resources, need and perhaps desire to go shopping and their respective hunts could potentially lead them to at least evaluating IBBJ holdings,” adds Nasdaq.For more news, information, and strategy, visit the Nasdaq Investment Intelligence Channel.

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.